Now Reading: US FDA flags 3 issues at Dr Reddy’s Srikakulam plant
-
01
US FDA flags 3 issues at Dr Reddy’s Srikakulam plant
Dr Reddy’s Laboratories has received three observations from the US Food and Drug Administration after an inspection at its Srikakulam facility in Andhra Pradesh. The Pre-Approval Inspection and Good Manufacturing Practices check…
The Story in Brief
Dr Reddy’s Laboratories has received three observations from the US Food and Drug Administration after an inspection at its Srikakulam facility in Andhra Pradesh. The Pre-Approval Inspection and Good Manufacturing Practices check were carried out from July 20 to July 29, the company said in a filing on July 29. The regulator issued a Form 483 with three observations, which the drugmaker said it would address within the stipulated timeline. Shares of Dr Reddy's closed flat at Rs 1,144.35 on the BSE on Thursday. The facility is the FTO-SEZ Process Unit-02.
The Indian Opinion
The three US FDA observations at Dr Reddy's Srikakulam unit will stir familiar anxieties about Indian pharma quality. But a Form 483 is a routine list of potential violations, not a final judgement. Dozens of Indian plants face these each year, and many resolve them without penalties. The real test will come when the company files its response: how many observations are classified as 'official action indicated'? That number, not the count itself, decides whether investors lose sleep or move on. Watch for the FDA's next communication to judge the gravity.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
